Western University of Health Sciences College of Osteopathic Medicine of the Pacific, Pomona, California, USA.
University of California Irvine Medical Center, Orange, California, USA.
J Neurointerv Surg. 2020 Oct;12(10):957-963. doi: 10.1136/neurintsurg-2019-015702. Epub 2020 Mar 18.
Flow modulation is the newest endovascular technique for treatment of cerebral aneurysms.
To investigate changes in aneurysm treatment practice patterns in the USA.
From the 2007 to 2016, the National Inpatient Sample databases, hospital discharges associated with unruptured aneurysms (UA), and/or ruptured aneurysms (RA) having undergone surgical clipping (SC) and/or endovascular treatments (EVT) were identified using the International Classification of Diseases codes. Patient demographics, hospital characteristics, and clinical outcomes were reviewed. Five year subgroup analyses were performed for treatment differences.
A total of 39 282 hospital discharges were identified with a significant increase in EVT (UA: SC n=7847 vs EVT n=12 797, p<0.001; RA: SC n=8108 vs EVT n=10 530, p<0.001). Hospitals in the South demonstrated the most significant EVT use regardless of aneurysm status (UA: SC n=258.5±53.6 vs EVT n=480.7±155.8, p<0.001; RA: SC n=285.6±54.3 vs EVT n=393.3±102.9, p=0.003). From 2007 to 2011, there was no significant difference in the mean number of cases for the treatment modalities (UA: SC n=847.4±107.7 vs EVT n=1120.4±254.1, p=0.21; RA: SC n=949.4±52.8 vs EVT n=1054.4±219.6, p=0.85). Comparatively, from 2012 to 2016, significantly more UA and RA were treated endovascularly (UA: SC n=722.0±43.4 vs EVT n=1439.0±419.2, p<0.001; RA: SC n=672.2±61.4 vs EVT n=1051.6±330.2, p=0.02).
As technological innovations continue to advance the neuroendovascular space, the standard of care for treatment of cerebral aneurysms is shifting further towards endovascular therapies over open surgical approaches in the USA.
血流调节是治疗脑动脉瘤的最新血管内技术。
调查美国动脉瘤治疗实践模式的变化。
使用国际疾病分类代码,从 2007 年至 2016 年,确定了未破裂动脉瘤(UA)和/或破裂动脉瘤(RA)的国家住院患者样本数据库和医院出院患者,这些患者接受了手术夹闭(SC)和/或血管内治疗(EVT)。回顾了患者人口统计学、医院特征和临床结果。对治疗差异进行了五年的亚组分析。
共确定了 39282 例医院出院患者,EVT 显著增加(UA:SC n=7847 与 EVT n=12797,p<0.001;RA:SC n=8108 与 EVT n=10530,p<0.001)。无论动脉瘤状态如何,南部的医院显示出最显著的 EVT 使用(UA:SC n=258.5±53.6 与 EVT n=480.7±155.8,p<0.001;RA:SC n=285.6±54.3 与 EVT n=393.3±102.9,p=0.003)。从 2007 年到 2011 年,治疗方式的平均病例数没有显著差异(UA:SC n=847.4±107.7 与 EVT n=1120.4±254.1,p=0.21;RA:SC n=949.4±52.8 与 EVT n=1054.4±219.6,p=0.85)。相比之下,从 2012 年到 2016 年,更多的 UA 和 RA 接受了血管内治疗(UA:SC n=722.0±43.4 与 EVT n=1439.0±419.2,p<0.001;RA:SC n=672.2±61.4 与 EVT n=1051.6±330.2,p=0.02)。
随着技术创新不断推进神经血管内空间,美国治疗脑动脉瘤的标准治疗方法正从开颅手术方法进一步转向血管内治疗。